Are CD40, CTLA4, and SH2B3 variants linked to autoimmune thyroid disease risk?

Autoimmune thyroid diseases (AITD), such as Hashimoto's thyroiditis and Graves' disease, are heavily influenced by key genetic variations that disrupt immunological checkpoints and compromise peripheral self-tolerance.

Immunological mechanisms of risk variants

• CD40 (rs1883832): This promoter polymorphism increases CD40 expression on antigen-presenting and B cells, lowering the threshold for costimulation and promoting germinal center formation.
• CTLA4 (rs231775 / +49 A/G): This missense variant impairs the inhibitory trafficking of CTLA-4, compromising T-cell checkpoint regulation and allowing autoreactive T-cell clones to escape peripheral deletion.
• SH2B3 (rs3184504): This hypomorphic variant disrupts negative feedback of the JAK-STAT cytokine signaling pathway, resulting in hyper-responsive effector T- and B-cell responses.

Clinical risk and antibody alignment

• Autoantibody production: The systemic loss of lymphocyte tolerance driven by these variants directly correlates with the generation of thyroid peroxidase (TPO) and thyroglobulin (Tg) antibodies.
• Titer correlations: Clinical evidence links the CTLA4 rs231775 and CD40 rs1883832 alleles directly to significantly elevated TPOAb and TgAb titers, orchestrating the classic antibody-positive autoimmune phenotype. While CD40 is more strongly associated with Graves' disease, CTLA4 variants represent a shared risk factor across both Graves' and Hashimoto's thyroiditis.

Bottom line

• Genetic variants in CD40, CTLA4, and SH2B3 disrupt key immune checkpoints to promote lymphocyte hyper-activation, directly driving susceptibility to autoimmune thyroid disease and the production of elevated TPO and Tg autoantibodies.